Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guizhou Medical Univ. WRN helicase compound 9
- Development stage
- Unknown
- Lead developer
- Guizhou Medical University
01
Overview
Guizhou Medical Univ. WRN helicase compound 9: sourced facts only. name: "This result indicates that the quinazoline derivative 9 could be a novel WRN function inhibitor for the treatment of prostate cancer." [PMID:39571305]; target: "This result indicates that the quinazoline derivative 9 could be a novel WRN function inhibitor for the treatment of prostate cancer." [PMID:39571305]; developer: "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China; Natural Products Research Center of Guizhou Province, Guiyang 550014, China." [PMID:39571305]
02
Targets
WRN (Werner syndrome ATP-dependent helicase)
Beyond the preview
Go deeper on Guizhou Medical Univ. WRN helicase compound 9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guizhou Medical Univ. WRN helicase compound 9.